Pre- and post-vaccination characteristics and risk factors for COVID-19 outcomes in a Swedish population-based cohort of COPD patients.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
14
12
2022
accepted:
09
05
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Evidence on risk factors for Coronavirus disease 2019 (COVID-19) outcomes among patients with COPD in relation to COVID-19 vaccination remains limited. The objectives of the present study were to characterise determinants of COVID-19 infection, hospitalisation, intensive care unit (ICU) admission and death in COPD patients in their unvaccinated state compared to when vaccinated. We included all COPD patients in the Swedish National Airway Register (SNAR). Events of COVID-19 infection (test and/or healthcare encounter), hospitalisation, ICU admission and death were identified from 1 January 2020 to 30 November 2021. Using adjusted Cox regression, associations between baseline sociodemographics, comorbidities, treatments, clinical measurements and COVID-19 outcomes, during unvaccinated and vaccinated follow-up time, were analysed. The population-based COPD cohort included 87 472 patients, among whom 6771 (7.7%) COVID-19 infections, 2897 (3.3%) hospitalisations, 233 (0.3%) ICU admissions and 882 (1.0%) COVID-19 deaths occurred. During unvaccinated follow-up, risk of COVID-19 hospitalisation and death increased with age, male sex, lower education, non-married status and being foreign-born. Comorbidities increased risk of several outcomes, This study provides population-based evidence on predictive risk factors for COVID-19 outcomes and highlights the positive implications of COVID-19 vaccination for COPD patients.
Identifiants
pubmed: 37377661
doi: 10.1183/23120541.00711-2022
pii: 00711-2022
pmc: PMC10291311
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflict of interest: L.E.G.W. Vanfleteren has received grants and personal fees from AstraZeneca, and personal fees from GSK, Novartis, Boehringer Ingelheim, Menarini, Resmed, Chiesi, AGA Linde, Zambon and Pulmonx. Conflict of interest: S. Franzén is an employee of AstraZeneca as of October 2021 but the work in this paper relates to the period prior to this. Conflict of interest: C. Stridsman has received personal fees from AstraZeneca, Boehringer Ingelheim and Novartis for lectures at sponsored meetings. Conflict of interest: F. Nyberg was an employee of AstraZeneca until 2019 and holds some AstraZeneca shares. Conflict of interest: B.K. Kirui, A. Santosa and H. Li have nothing to disclose.
Références
J Allergy Clin Immunol. 2021 Feb;147(2):510-519.e5
pubmed: 33068560
Thorax. 2002 Oct;57(10):847-52
pubmed: 12324669
Chronic Obstr Pulm Dis. 2021 Apr 27;8(2):255-268
pubmed: 33780602
Med Sci Monit. 2020 Sep 04;26:e927212
pubmed: 32883943
J Am Med Dir Assoc. 2017 Dec 1;18(12):1097.e11-1097.e24
pubmed: 29169740
PLoS One. 2021 Jun 3;16(6):e0252576
pubmed: 34081722
Obes Med. 2020 Sep;19:100283
pubmed: 32835126
Lancet. 2007 Sep 1;370(9589):786-96
pubmed: 17765528
Biol Sex Differ. 2020 Sep 18;11(1):53
pubmed: 32948238
J Epidemiol Community Health. 2022 Jan 7;:
pubmed: 34996808
Int J Epidemiol. 2020 Oct 1;49(5):1468-1481
pubmed: 32887982
ERJ Open Res. 2016 Jul 07;2(3):
pubmed: 27730201
Lancet Respir Med. 2020 Nov;8(11):1106-1120
pubmed: 32979987
Int J Obes (Lond). 2021 Sep;45(9):2028-2037
pubmed: 34112941
J Thorac Dis. 2020 May;12(5):1811-1823
pubmed: 32642086
Eur Clin Respir J. 2020 Oct 23;7(1):1833412
pubmed: 33224453
J Migr Health. 2021;3:100041
pubmed: 33903857
PLoS One. 2020 May 11;15(5):e0233147
pubmed: 32392262
Tuberc Respir Dis (Seoul). 2022 Jan;85(1):74-79
pubmed: 34775736
Medicine (Baltimore). 2016 Jul;95(28):e4225
pubmed: 27428228
Clin Epidemiol. 2021 Jul 30;13:649-659
pubmed: 34354377
Lancet Respir Med. 2022 Sep;10(9):900-915
pubmed: 35985357
J Autoimmun. 2012 May;38(2-3):J245-53
pubmed: 22209097
SN Compr Clin Med. 2020;2(8):1069-1076
pubmed: 32838147
Bull Eur Physiopathol Respir. 1985 Nov-Dec;21(6):551-7
pubmed: 4074961
Eur Respir J. 2021 Nov 11;58(5):
pubmed: 34413151
Eur J Epidemiol. 2019 Apr;34(4):423-437
pubmed: 30929112
Eur J Epidemiol. 2021 Mar;36(3):287-298
pubmed: 33704634
Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22
pubmed: 9603117
J Clin Med. 2020 Oct 12;9(10):
pubmed: 33053774
Thorax. 2021 May;76(5):512-513
pubmed: 33273024
J Allergy Clin Immunol Pract. 2021 Jan;9(1):160-169
pubmed: 33038592
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
EClinicalMedicine. 2020 Sep;26:100515
pubmed: 32869011
SN Compr Clin Med. 2020;2(7):874-876
pubmed: 32838138
Am J Epidemiol. 2013 Feb 15;177(4):292-8
pubmed: 23371353